iShares Global Healthcare

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?

MGRX

ARKG

SBIO

LABU

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

TradingView

Mangoceuticals

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Health Care Select Sector SPDR

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Pfizer Inc. (PFE) shares rose 1.30% to $25.66 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Eli Lilly. Despite the gain, Pfizer remains 10.73% below its 52-week high of $28.75. The trading volume reached 40.9 million, surpassing its 50-day average of 37.8 million.

- Shares of Pfizer Inc. (PFE) increased by 1.30% to $25.66 amid a generally negative trading day for the stock market.  
- The stock remains 10.73% below its 52-week high of $28.75, reached on April 2nd, while competitors like Johnson & Johnson and Eli Lilly saw gains.  
- Trading volume for Pfizer was 40.9 million, surpassing its 50-day average of 37.8 million.

MarketWatch Automated

Pfizer

Invesco Nasdaq Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Eli Lilly

Abbott Laboratories

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

AMGN

Amgen Inc. (AMGN) shares rose 1.96% to $330.75 on a weak trading day for the market, breaking a three-day losing streak. Despite this gain, the stock remains 15.47% below its 52-week high of $391.29. Competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, with trading volume surpassing its 50-day average.

Amgen

Abbvie

Factset Research

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

Regencell Bioscience has announced a registered direct offering of 985,222 ordinary shares priced at $20.30 each, aiming for gross proceeds of approximately $20 million. The offering is led by a $19 million investment from a new institutional investor, with closing expected around May 20, 2026, subject to customary conditions. Univest Securities is the sole placement agent.

PUBT

Regencell Bioscience

Univest Financial

Regencell Bioscience prices 985,222-share registered direct offering at $20.30 each

ABBV

AbbVie Inc. (ABBV) shares rose 2.08% to $213.76 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Pfizer. The stock ended 12.68% below its 52-week high of $244.81. Trading volume reached 7.1 million, surpassing the 50-day average of 6.9 million.

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

ETON

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights to the leishmaniasis drug IMPAVIDO (miltefosine) through a supply and distribution agreement with a Knight Therapeutics affiliate. The rights will take effect on September 26, 2026, contributing to Eton's rare disease portfolio and marking another product launch planned for that year. IMPAVIDO is the only FDA-approved oral treatment for certain forms of leishmaniasis.

Eton Pharmaceuticals

Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido

OCUL

Ocular Therapeutix reported Q1 2026 results with revenue of $10.79 million and a net loss of $88.61 million, indicating a significant investment burden despite stable revenue. The company's future hinges on the success of its AXPAXLI trials, with a projected revenue of $335.8 million by 2029. Analysts express concerns over rising losses and dependence on AXPAXLI, with fair value estimates ranging from $18.00 to $26.00 per share.

Simplywall

Ocular Therap

Tenet Healthcare's recent performance shows promising hospital foot traffic, suggesting stronger-than-expected second-quarter volumes. Executives presented at the Bank of America Global Healthcare Conference, highlighting disciplined capital returns and a revenue forecast of $21.5 billion to $22.3 billion for 2026. Despite concerns over high leverage and insider selling, the stock may be undervalued, with fair value estimates ranging significantly. Investors are encouraged to consider these factors in their investment decisions.

Tenet Healthcare

Bank of America

NVIDIA

Microsoft

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

NVIDIA Corporation

The Bull Case For Tenet Healthcare (THC) Could Change Following April Foot Traffic And Volume Signals

RYTM

Rhythm Pharmaceuticals' CAO Christopher Paul German sold 4,643 shares for $428,131.03 on May 15, 2026, reducing his holdings to zero. The shares were sold at $92.21 each, following option exercises for 4,442 shares at strike prices between $17.97 and $56.69.

Rhythm Pharma

Rhythm Pharma Controller, CAO Christopher Paul German disposes 4,643 shares worth $428,131.03

ANVS

Annovis Bio has launched an underwritten public offering of common stock with warrants. The stock and warrants will be sold as a combined package, with Canaccord Genuity as the sole bookrunner. Proceeds will support Phase 3 development of buntanetap for Alzheimer's disease, along with working capital and general corporate purposes.

Annovis Bio

Annovis Bio launches underwritten public offering of common stock with warrants

On May 19, 2026, the S&P 500 closed lower due to rising inflation expectations and higher long-term yields. The healthcare sector outperformed, led by stocks like Becton Dickinson and Eli Lilly, as they are less affected by rising yields. Conversely, the materials sector struggled with declining gold and silver prices, impacted by a stronger dollar, with stocks like Newmont Mining and DuPont seeing losses.

Tip Ranks

Newmont

Becton Dickinson and

Direxion Daily Gold Miners Bull 2X

Wisdomtree Efficient Gold Plus Gold Miners Stgy Fd - ETF

iShares US Medical Devices

iShares MSCI Global Gold Miners

Tradr 2X Long NEM Daily ETF

VanEck Junior Gold Miners ETF

VanEck Gold Miners ETF

Defiance Daily Target 2X Long LLY ETF

Us Gbl GLD & Met

Sprott GLD Miners Etf

SPDR S&P Health Equip

Baxter

DexCom

Bio-Techne

DuPont de Nemours

Martin Marietta Materials

Albemarle

CRH Plc

DUPONT DE NEMOURS INC

Top Stock Gainers Today, 5/19/26

Novo Nordisk AS

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

iShares Global Healthcare(IXJ.US)

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

Regencell Bioscience prices 985,222-share registered direct offering at $20.30 each

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day